((自动化翻译由路透提供，请见免责声明 ))
10月30日 - ** 辉瑞 首席执行官阿尔伯特-布尔拉（Albert Bourla）在激进分子 (link) 对冲基金Starboard Value的压力下，周二向华尔街证明，由于COVID-19治疗药物Paxlovid销售强劲，辉瑞的扭亏为盈正在取得成功。
专注于产品线
** Leerink Partners("市场表现"，目标价：31 美元) 称产品线评论令人鼓舞，但长期前景仍受到十年末专利到期压力的挑战；认为 2024 年财务指导偏保守。
** 巴克莱银行（Barclays）("等权重"，预期收益率：32 美元) 表示，投资者需要结合管线获胜、研发基础设施的合理规模以及资本分配的证据，才能对十年后半期的盈利状况有更多的了解。
** 摩根士丹利("等权重"，公允价值：31 美元) 预计新产品周期的执行和/或有意义的管线进展仍将是未来关注的焦点。
** Morningstar(公允价值：42 美元) 指出，尽管该公司非 Covid 产品线强劲的运营销售增长令人鼓舞，但现有药物的激烈竞争正在拖累辉瑞的产品线。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.